These Analysts Revise Their Forecasts On DexCom Following Q3 Results
These Analysts Revise Their Forecasts On DexCom Following Q3 Results
DexCom shares fell 1.6% to trade at $73.68 on Friday.DexCom, Inc. (NASDAQ:DXCM) reported better-than-expected third-quarter results on Thursday.
德康医疗公司（纳斯达克股票代码：DXCM）于周四发布了优于预期的第三季度业绩。
DexCom reported quarterly earnings of 45 cents per share, which beat the analyst consensus estimate of 43 cents. Quarterly revenue came in at $994.2 million which beat the analyst consensus estimate of $990.71 million and is an increase over sales of $975 million from the same period last year.
德康医疗报告每股45美分的季度收益，超过了分析师共识预估的43美分。季度营业收入达到99420万美元，超过了分析师共识预估的99071万美元，并较去年同期的97500万美元销售额有所增加。
DexCom also announced Teri Lawver, executive vice president and chief commercial officer, will retire at the end of the year. Lawver will continue as a special advisor to Dexcom through early 2025 and Kevin Sayer, chairman, president and CEO, will assume leadership of the commercial organization as the company conducts a global search for a new chief commercial officer.
DexCom还宣布，首席商业官兼执行副总裁Teri Lawver将于年底退休。Lawver将继续担任Dexcom的特别顾问，直到2025年初，董事长、总裁兼首席执行官Kevin Sayer将在公司为新的首席商业官进行全球搜寻的同时，负责领导商业机构。
DexCom shares fell 1.6% to trade at $73.68 on Friday.
德康医疗股价周五下跌1.6％，报73.68美元。
These analysts made changes to their price targets on DexCom following earnings announcement.
这些分析师在德康医疗发布财报后调整了其目标价。
- Wells Fargo analyst Larry Biegelsen maintained DexCom with an Overweight and raised the price target from $80 to $90.
- Leerink Partners analyst Mike Kratky maintained DexCom with an Outperform and lowered the price target from $90 to $87.
- JP Morgan analyst Robbie Marcus maintained the stock with a Neutral and raised the price target from $75 to $85.
- Oppenheimer analyst Steven Lichtman maintained DexCom with an Outperform and lowered the price target from $115 to $105.
- RBC Capital analyst Shagun Singh maintained the stock with an Outperform and lowered the price target from $120 to $115.
- Bernstein analyst Lee Hambright maintained DexCom with an Outperform and raised the price target from $82 to $86.
- Raymond James analyst Jayson Bedford maintained DexCom with a Strong Buy and lowered the price target from $115 to $99.
- 富国银行分析师Larry Biegelsen维持对德康医疗的买入评级，并将目标股价从80美元上调至90美元。
- Leerink合伙人分析师Mike Kratky维持对德康医疗的跑赢评级，并将目标股价从90美元下调至87美元。
- 摩根大通分析师Robbie Marcus维持了中立看法，并将目标股价从75美元上调至85美元。
- Oppenheimer分析师史蒂文·利希特曼维持德康医疗的买入评级，并将目标价从115美元下调至105美元。
- RBC Capital分析师沙甘·辛格保持该股票的买入评级，将目标价从120美元下调至115美元。
- 伯恩斯坦分析师李·汉布赖特维持德康医疗的买入评级，并将目标价从82美元上调至86美元。
- Raymond James分析师杰森·贝德福德维持德康医疗的强烈买入评级，并将目标价从115美元下调至99美元。
- How To Earn $500 A Month From Waste Management Stock Ahead Of Q3 Earnings
- 如何在Q3收益之前从废物管理股票中赚取每月500美元
